CVS Health Corporation (CVS) Position Boosted by Bollard Group LLC
Bollard Group LLC raised its stake in shares of CVS Health Corporation (NYSE:CVS) by 0.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,415 shares of the pharmacy operator’s stock after buying an additional 25 shares during the period. Bollard Group LLC’s holdings in CVS Health Corporation were worth $1,562,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in the stock. LSV Asset Management raised its position in CVS Health Corporation by 44.2% in the first quarter. LSV Asset Management now owns 4,579,916 shares of the pharmacy operator’s stock valued at $359,523,000 after buying an additional 1,404,384 shares during the last quarter. Macquarie Group Ltd. raised its position in CVS Health Corporation by 16.6% in the fourth quarter. Macquarie Group Ltd. now owns 9,526,280 shares of the pharmacy operator’s stock valued at $751,719,000 after buying an additional 1,359,100 shares during the last quarter. NN Investment Partners Holdings N.V. raised its position in CVS Health Corporation by 141.2% in the second quarter. NN Investment Partners Holdings N.V. now owns 1,427,210 shares of the pharmacy operator’s stock valued at $114,832,000 after buying an additional 835,476 shares during the last quarter. Swiss National Bank raised its position in CVS Health Corporation by 26.9% in the first quarter. Swiss National Bank now owns 3,826,410 shares of the pharmacy operator’s stock valued at $300,373,000 after buying an additional 811,100 shares during the last quarter. Finally, Karp Capital Management Corp purchased a new position in CVS Health Corporation during the first quarter valued at about $55,824,000. 81.92% of the stock is currently owned by institutional investors and hedge funds.
CVS Health Corporation (NYSE:CVS) traded up 0.4493% on Friday, reaching $79.4956. The company had a trading volume of 1,491,417 shares. The firm has a market capitalization of $80.81 billion, a PE ratio of 15.8358 and a beta of 0.91. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $98.44. The stock has a 50 day moving average of $78.77 and a 200 day moving average of $78.97.
CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.02. The business had revenue of $45.69 billion during the quarter, compared to analyst estimates of $45.36 billion. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.32 EPS. On average, analysts anticipate that CVS Health Corporation will post $5.88 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, August 3rd. Shareholders of record on Monday, July 24th were given a $0.50 dividend. The ex-dividend date was Thursday, July 20th. This represents a $2.00 dividend on an annualized basis and a yield of 2.53%. CVS Health Corporation’s dividend payout ratio (DPR) is 39.92%.
Several equities analysts recently issued reports on the company. Vetr lowered CVS Health Corporation from a “buy” rating to a “hold” rating and set a $85.78 target price on the stock. in a research note on Thursday, April 27th. Tigress Financial assumed coverage on CVS Health Corporation in a research note on Thursday, April 27th. They set a “buy” rating on the stock. Needham & Company LLC assumed coverage on CVS Health Corporation in a research note on Tuesday, June 27th. They set a “hold” rating on the stock. Guggenheim reissued a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Finally, Leerink Swann set a $90.00 target price on CVS Health Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Eight research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $91.27.
In other CVS Health Corporation news, EVP Helena Foulkes sold 20,333 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $80.00, for a total value of $1,626,640.00. Following the completion of the sale, the executive vice president now directly owns 59,301 shares in the company, valued at $4,744,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David M. Denton sold 230,510 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.00, for a total value of $18,440,800.00. Following the completion of the sale, the chief financial officer now owns 176,983 shares of the company’s stock, valued at $14,158,640. The disclosure for this sale can be found here. Insiders sold 271,175 shares of company stock valued at $21,632,597 over the last 90 days. 0.61% of the stock is currently owned by insiders.
About CVS Health Corporation
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.